Investors Research Corp’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Investors Research Corp’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-89	Closed	–	–	1162
2022 Q3	$0	Hold	89	–	–	﹤0.01%	1172
2022 Q2	$0	Hold	89	–	–	﹤0.01%	1195
2022 Q1	$0	Hold	89	–	–	﹤0.01%	1131
2021 Q4	$0	Hold	89	–	–	﹤0.01%	1083
2021 Q3	$0	Hold	89	–	–	﹤0.01%	1063
2021 Q2	$0	Hold	89	–	–	﹤0.01%	1048
2021 Q1	$1K	Sell	89 -20	-18%	-$165	﹤0.01%	961
2020 Q4	$1K	Hold	109	–	–	﹤0.01%	1062
2020 Q3	$1K	Buy	+109	New	+$827	﹤0.01%	1075

Investors Research Corp's LOGC Position: Q4 2022 in Review

Investors Research Corp sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 89 shares.

Investors Research Corp first reported a position in LOGC in Q3 2020 and held it in 9 quarters. The position peaked at $1K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Investors Research Corp reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Investors Research Corp sold 89 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Investors Research Corp first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Investors Research Corp's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Investors Research Corp's 13F filing for Q4 2022, filed 6 Feb 2023.